174MO The A2AR antagonist inupadenant promotes humoral responses in patients
interactions.WES analysis showed LOH of one HLA-II isotype in 10/76 non-acral cutaneous melanoma samples (2/9 patients), and only in 1/52 acral/mucosal samples (1/5 patients), suggesting immune editing may drive HLA-II loss. Conclusions:Our findings indicate a link between melanoma dedifferentiation, CD4+ TIL recognition via HLA-DR, and HLA-II loss.Recognition of HLA-II+ melanomas is preferentially mediated via HLA-DR, but LOH might impact neoantigen presentation, leading to immune evasion.
Authors
- Paola Tieppo
- Nicolas Rosewick (ORCID: https://orcid.org/0000-0002-4443-2492)
- Chiara Martinoli (ORCID: https://orcid.org/0000-0002-8173-5046)
- Stephanie Ma (ORCID: https://orcid.org/0000-0002-2029-7943)
- Yvonne McGrath (ORCID: https://orcid.org/0000-0001-6564-7700)
- Francesco Strozzi (ORCID: https://orcid.org/0000-0002-6845-6982)
- Hussein Shehade (ORCID: https://orcid.org/0000-0003-4052-6309)
- Maria Lucia Rosa Rossetti
Institutions
- Bone Therapeutics (BE)
- Biomarker Strategies (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100927
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Francis Crick Institute
- Gordon and Rose McAlpine Foundation for Neuroscience Research
- Cancer Research UK
- National Institute for Health and Care Research
- Novo Nordisk
- H. Lundbeck A/S